Modella AI vs Nucleai (2026)
Two research grade pathology AI companies aimed at pharmaceutical customers rather than at diagnostic laboratories, and they measure different things. Nucleai does spatial biology, integrating high plex proteomics with histopathology and clinical data to find predictive spatial biomarkers, on the argument that where cells sit relative to each other carries signal no pathologist can practically quantify. Modella builds generative and agentic tooling on pathology foundation models, including a conversational co pilot over the slide. For a trial stratification or immunotherapy response question, Nucleai is measuring the thing being asked about. For a group exploring what foundation models can do across many questions, Modella is the general purpose layer. Neither is a cleared diagnostic, so any clinical use is a decision the laboratory makes rather than one a regulator has reviewed.
- The platform integrates high plex spatial proteomics with histopathology and clinical data to find spatial biomarkers, which is a different measurement from cell counting or classification.
- Its stated capability is to detect spatial relationships human readers cannot practically assess, and named pharmaceutical partnerships support the research side of that claim.
- For a pharmaceutical team stratifying patients for immunotherapy response, spatial context is where the signal has been found repeatedly.
- Foundation models pretrained on pathology support a conversational co pilot, which reaches tasks nobody wrote a dedicated algorithm for.
- Generative and agentic tooling is a different layer from biomarker analysis, aimed at how a pathologist interacts with the slide archive rather than at a specific readout.
- For a department exploring what these models can do across many questions, a general purpose layer is more useful than a single biomarker platform.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Modella AI and Nucleai are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Modella AI | Nucleai |
|---|---|---|
| Primary category | Digital Pathology AI | Digital Pathology AI |
| Founded | 2023 | 2016 |
| Headquarters | Boston, Massachusetts, United States | Tel Aviv, Israel |
| Website | modella.ai | nucleai.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Modella AI its top capability grade on AI Centrality and Model and Technology Transparency. Set against Nucleai, Modella AI grades higher on Model and Technology Transparency, AI Liability and Recourse and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Nucleai its top capability grade on AI Centrality. Set against Modella AI, Nucleai grades higher on Clinical and Operational Evidence. Its thinnest published disclosure sits on Model Supply Chain Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Modella AI or Nucleai?
On the axes where the AI Health Index separates them, Modella AI grades higher on Model and Technology Transparency, AI Liability and Recourse and Setting and Specialty Coverage, and Nucleai grades higher on Clinical and Operational Evidence. Modella AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Modella AI and Nucleai differ most?
The widest separation the AI Health Index records between Modella AI and Nucleai is on Model and Technology Transparency, where Modella AI grades A and Nucleai grades B. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do Modella AI and Nucleai grade the same?
The AI Health Index grades Modella AI and Nucleai the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Modella AI and Nucleai not disclosed?
At the last review, at least one of Modella AI and Nucleai published thin or absent detail on Model Supply Chain Disclosure. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Digital Pathology AI page.
Neither vendor is a cleared diagnostic and neither should be read as one: both produce research grade output that informs decisions rather than making them, and any clinical use is a decision the laboratory owns. Nucleai publishes no health privacy or data governance framework despite processing patient biopsy images correlated with clinical data, and no attestation was located for either company. Neither publishes pricing. For both, the uncontrolled variable is preparation: multiplex staining and scanning protocols vary between sites and neither vendor publishes performance across that variation.